The EULAR COVID-19 Registry closed on the last day of the EULAR 2022 Congress. Since March 2020, the EULAR/Global Rheumatology Alliance partnership has facilitated the collection of 12,861 COVID-19 cases in the EULAR Registry, and over 22,000 in total across global provider registries. The information collected has informed clinical practice and the development of new recommendations.
EULAR would like to sincerely thank all the rheumatologists, physicians, epidemiologists, healthcare professionals, national societies, and patients who contributed to and supported this important initiative.
About the EULAR - COVID-19 Registry
The EULAR - COVID-19 Registry is a European paediatric and adult registry (in collaboration with the Pediatric Rheumatology European Society (PReS)) to monitor and report on outcomes of “Coronavirus Disease 2019” (COVID-19) occurring in patients with rheumatic and musculoskeletal diseases (RMDs). The Registry closed in June 2022 after almost 2 years of collecting cases worldwide. The registry helped to understand outcomes of patients who acquired “severe acute respiratory syndrome coronavirus 2” (SARS-CoV‐2) infection and who received steroids, synthetic or biologic disease-modifying anti-rheumatic drugs (DMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs). The data collected will continue to guide rheumatologists and other clinicians such as specialist nurses in advising and caring for their patients.
We are grateful to our international colleagues who have established the COVID-19 Global Rheumatology Alliance1 and helped us establish this registry. Anonymised data will be shared with this international registry, based in the United States.
Partner national registers
FAQs (Frequently asked questions)
See frequently asked questions about the EULAR COVID-19 Registry.
The EULAR-COVID-19 Registry steering group
|Pedro Machado, United Kingdom
Rheumatologist & Epidemiologist, Chair of the EULAR Standing Committee of Epidemiology and Health Services Research (SCEHSR); University College London (UCL), London, UK
|Elsa Mateus, Portugal
Patient Representative & Chair of the EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE); Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal
|Laure Gossec, France
Rheumatologist & Epidemiologist, Past-Chair of the EULAR Standing Committee of Epidemiology and Health Services Research (SCEHSR);Sorbonne Universite and Pitie Salpetriere Hospital, Paris, France
|Kimme Hyrich, United Kingdom
Rheumatologist & Epidemiologist, UK Centre for Epidemiology Versus Arthritis, Manchester, UK
|Anja Strangfeld, Germany
Physician & Epidemiologist, Epidemiology Unit, German Rheumatism Research Centre (DRFZ), Berlin, Germany
Loreto Carmona, Spain
EULAR-COVID-19 Country Leads
France: Christophe Richez, Éric Hachulla
Germany: Rebecca Hasseli
Greece: Charalampos Papagoras
Italy: Carlo Scirè
Portugal: Maria José Santos
Sweden: Lotta Ljung
The EULAR COVID-19 Registry is based on rheumatologists and other clinicians voluntarily reporting cases, meaning that patients included do not necessarily represent the majority of patients with RMDs and COVID-19, but those who their doctors reported data to the Registry. Additionally, this registry does not account for non-COVID-19 patients. Therefore, results cannot be directly extrapolated to the entire population of patients with RMDs and COVID-19, and should be interpreted cautiously. For research purposes and proper considerations, this data requires adequate analysis, further adjustments and stratifications.
1 The COVID-19 Global Rheumatology Alliance. Website: rheum-covid.org
28 April 2022
EULAR COVAX Registry
EULAR has set up a very simple survey to be filled in online after consultation with an RMD patient any time after her/his first or second injection of COVID-19 vaccination.
Papers using the combined EULAR & Global Registry Data
Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases
EULAR COVID-19 registry: lessons learnt and future considerations
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
If you have any questions about these registries please send an e-mail to firstname.lastname@example.org .
Please note that this email address is for technological clarifications about the Registry and NOT for patient data and queries.